Today (August 21), the leading medical aesthetics company IMEiK Technology Development Co., Ltd. (referred to as IMEiK) released its financial report for the first half of 2024.
During the reporting period, IMEiK achieved an operating income of 1.656 billion yuan ($232.1 million), a year-on-year increase of 13.53%; the total profit reached 1.304 billion yuan ($182.2 million), a year-on-year increase of 16.95%; and the net profit was 1.121 billion yuan ($157.1 million), a year-on-year increase of 16.67%.
Public information shows that IMEiK is a national high-tech enterprise engaged in the research and development and commercialization of biomedical materials and biopharmaceutical products. The company has successfully industrialized a series of skin fillers based on sodium hyaluronate, skin fillers based on polylactic acid, and facial embedding threads made of polydioxanone. They are also currently developing biopharmaceutical products such as recombinant proteins and peptides.
By department, IMEiK’s revenue mainly comes from gel injection products and solution injection products. Among them, solution injection products achieved an operating income of 976 million yuan, an increase of 11.65% compared to the same period last year. The core solution product, “HiBody,” is the first Class III medical device product certified by the National Medical Products Administration for correcting moderate to severe neck wrinkles.
Gel injection products achieved an operating income of 649 million yuan ($90.97 million), an increase of 14.57% compared to the same period last year. The core gel product, “RUBY Angel,” has been fully recognized by downstream medical institutions and end consumers, with its brand influence increasingly rising.
